Biomarin Pharmaceutical (BMRN) Raw Materials (2010 - 2021)

Biomarin Pharmaceutical has disclosed Raw Materials across 12 years of filings, most recently posting $75.3 million for Q3 2021.

• Quarterly Raw Materials rose 1.99% year-over-year to $75.3 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $75.3 million (up 1.99% YoY) and the FY2020 annual result came in at $76.7 million, up 3.0% from the prior year.
• Raw Materials fell to $75.3 million in Q3 2021, from $83.7 million in the prior quarter.
• Over five years, Raw Materials peaked at $83.7 million in Q2 2021 and troughed at $46.5 million in Q2 2018.
• A 5-year average of $65.3 million and a median of $68.4 million in 2019 frame the typical range for Raw Materials.
• Annual changes were most pronounced in 2018 — Raw Materials jumped 49.6% — and 2021, when it slipped 4.42%.
• Tracing BMRN's Raw Materials over 5 years: stood at $49.9 million in 2017, then soared by 49.6% to $74.6 million in 2018, then declined by 0.23% to $74.4 million in 2019, then gained by 3.0% to $76.7 million in 2020, then declined by 1.75% to $75.3 million in 2021.
• Business Quant data shows BMRN's Raw Materials at $75.3 million in Q3 2021, $83.7 million in Q2 2021, and $78.6 million in Q1 2021.